<DOC>
	<DOCNO>NCT00172172</DOCNO>
	<brief_summary>This study evaluate effect calcium supplementation efficacy safety recombinant parathyroid hormone ( ALX1-11 ) postmenopausal woman osteoporosis . The primary objective clinical study evaluate whether increase bone mineral density ( BMD ) subject treated ALX1-11 receiving calcium supplementation le increase BMD observe subject treat ALX1-11 receive calcium supplementation .</brief_summary>
	<brief_title>Calcium Supplementation Postmenopausal Women</brief_title>
	<detailed_description>Effects ALX1-11 bone mineral density ( BMD ) document dose-finding Phase II clinical trial osteoporotic postmenopausal woman , supplement calcium Vitamin D3 without treatment osteoporosis . The anabolic effect ALX1-11 lumbar vertebra statistically significant 12-month treatment period pronounce approved therapy . Additionally , animal study show new bone form treatment ALX1 11 good quality histologically biomechanically . The primary objective clinical study evaluate whether increase bone mineral density ( BMD ) subject treated ALX1-11 receiving calcium supplementation le increase BMD observe subject treat ALX1-11 receive calcium supplementation . A secondary objective clinical study evaluate whether change efficacy parameter , bone mineral content ( BMC ) biochemical marker bone turnover , subject treat ALX1-11 receive calcium supplementation le increase observed subject treat ALX1-11 receive calcium supplementation . This double-blind , multi-centered , randomize , placebo-controlled , parallel-group study comprise 3 treatment group : ALX1-11 injection plus oral calcium , ALX1-11 injection plus oral placebo calcium , placebo ALX1-11 injection plus oral calcium . All subject also receive 400 IU oral vitamin D3 . The dose ALX1-11 use study 100 μg , self administer daily sc injection . The calcium dose 700 mg/day . Additional supplemental calcium and/or Vitamin D3 permit . Patients monitor development hypercalcemia and/or hypercalciuria .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Women capable understand give write , voluntary inform consent clinical study screen visit Women ability selfadminister daily injection designee give injection Women postmenopausal least one year since last menstruation . If subject 's menopausal status screen question , history subject hysterectomy without oophorectomy , folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL satisfy definition postmenopausal status . Women 4554 year age follow Tscore and/or vertebral fracture Tscore &gt; =3.0 standard deviation ( SD ) mean peak bone mass young woman lumbar spine , femoral neck , total hip Or Tscore &gt; =2.5 SD mean peak bone mass young woman lumbar spine , femoral neck , total hip prevalent vertebral fracture verify central image organization subject enrol study Women &gt; =55 year age follow Tscore and/or vertebral fracture : Tscore &gt; =2.5 SD mean peak bone mass young woman lumbar spine , femoral neck , total hip Or Tscore &gt; =2.0 SD mean peak bone mass young woman lumbar spine , femoral neck , total hip vertebral fracture verify central image organization subject enrol study The following type vertebral fracture consider subject enrollment study : Pathological fracture due malignant disease infection Fractures due excessive trauma sufficient cause fracture young individual normal bone mass A. Vertebral Deformity ( assess describe Appendix 2 protocol , sufficient exclusion ) : · Vertebral deformity Patient 5 vertebral ( thoracic lumbar ) fracture Patient 2 lumbar vertebral deformity ( L1 L4 ) B. DXA Imaging : · Inability DXA scan perform , e.g . : A history lumbar laminectomy interfere DXA measurement lumbar vertebra The presence pedicle screw The patient lay flat back required time provide accurate imaging Patient able A/P lumbar vertebral DXA perform Patient history vertebroplasty Any excessive degenerative disease interfere DXA measurement lumbar vertebra hip C. History Concurrent Illness : Disorders Immunity HIV Significant* immunological disorder Endocrine system Any history hyper hypoparathyroidism Cushing 's disease Hyperthyroidism ( within 12 month ) Significant* endocrine disorder Gastrointestinal system Significant* gastrointestinal disorder Kidney collect system Clinically significant* history nephrolithiasis urolithiasis Current impair renal function and/or verify kidney calcification* Significant* renal disorder Liver , biliary tract pancreatic system Active hepatitis pancreatitis Significant* hepatic pancreatic disorder Musculoskeletal system Any history metabolic bone disease within past 5 year , ( e.g. , Paget´s disease , osteogenesis imperfecta , osteomalacia ) Subjects chronic , active joint disease and/or joint infection Neoplasia Any history bone cancer cancer within previous 5 year , exception squamous basal cell carcinoma** ( ** ) Patients either squamous basal cell carcinoma skin enroll : 1 . The lesion ( ) fully resect clear margin describe write report pathologist , 2 . The patient recurrence lesion least one year time original resection . · Nervous system Significant* neurological psychiatric disease · Vascular , respiratory cardiac system Significant* unstable cardiac pulmonary disease ( * ) Significance determine investigator basis history , physical exam , and/or laboratory screen . Significant disorder necessitate ongoing change therapeutic medication frequent monitoring . D. Concurrent Medication : Patients enrol clinical trial receive follow therapy time : Any PTH PTH analog [ e.g. , rhPTH ( 184 ) , PTH ( 134 ) , PTHrP analogs ] Fluoride Strontium Patients must follow agent specify time enter screen phase clinical trial : Any investigational drug ( &gt; 30 day ) Anabolic steroid androgen ( &gt; 6 consecutive month ) Active Vitamin D3 metabolites analog , e.g. , calcitriol ( &gt; 90 day ) Provera ( medroxyprogesterone ) ( According label instruction ) Systemic corticosteroid , 5mg/day formulation equivalent 5mg/day prednisone ( &gt; 12 consecutive month acute bolus nonrecurring condition ) . A patient enrol study need receive acute bolus steroid ( oral injectable ) selflimited illness may continue treatment study follow requirement meet : The maximal dose steroid ( prednisone equivalent ) limit 225 mg ( 7.5 mg day 30 day ) The illness acute nature expect recur remain treatment period study Inhaled corticosteroid equivalent &lt; 1200 μg beclomethasone Bisphosphonates , include investigational bisphosphonates If patient receive bisphosphonates &gt; 90 day 12 month immediately screen , patient exclude study . If patient receive bisphosphonates 12 month time . *The patient may enrol : Has take bisphosphonates &gt; =30 day &lt; =90 day , complete washout equivalent time . No washout necessary patient take bisphosphonates &lt; 30 day . Intravenous ( IV ) pamidronate Patient receive 1 dose pamidronate &gt; 3 12 month immediately precede screen visit . Patient receive 1 dose within three month immediately prior screen visit Patient must receive &gt; 2 dos time screen . Cyclical Etidronate Patient exposure equal 9 month standard dose ( e.g. , 400 mg ) . Exposure cyclical etidronate must &lt; =6 month standard dose ( e.g. , 400 mg/day ) prior screen visit . Phenytoin seizure control : If patient receive phenytoin &lt; 5 year , patient exclude study The patient may continue screen process : &gt; =15 year pass since last dose phenytoin use 515 year screen visit patient receive phenytoin &lt; 2 month Patients may enrol stabilize follow therapy specify amount time : Thyroid Hormone ( &lt; 0.1 mg/day thyroxine ) therapy &gt; =6 month If take &gt; = 0.1 mg/day &lt; = 0.2 mg/day , must serum TSH level &gt; = 0.1 mU/L . Patients exclude take dos &gt; 0.2 mg/day . If patient minimal change Lthyroxine dose &lt; =0.025 mg/day within 6 month enrollment , new dose &gt; =2 month , may continue . The patient must history document Lthyroxine CRF . If patient require increase decrease thyroid replacement dose , enrol clinical study , increment decrement &lt; =0.025 mg/day , increment occur frequently per month , recommend physician caring patient . The patient must TSH thyroxine level within 3 month dose change ensure patient become hyperthyroid , hypothyroid . Thiazide ( Stable dosage thiazide &gt; =3 consecutive month ) All patient must stop follow therapy least 4 week start stabilization period remain therapy remainder clinical study . The informed consent must sign prior washout therapy . Screening laboratory must perform washout complete . However , image study ( BMD , Xrays ) may perform prior start calcitonin , estrogen , Selective Estrogen Receptor Modulation ( SERM ) washout . · Calcitonin Estrogen replacement therapy oral , transdermal , intramuscular administration Vaginal application estrogencontaining cream ( If conjugate estrogen estradiol : &lt; =0.5 g twice week [ total 1.0 g weekly ] medication allow ) SERM drug , e.g. , tamoxifen , raloxifene , Evista Cytostatics , e.g. , azathioprine , recombinant human tumor necrosis fusion ( Fc ) protein , monoclonal antibody tumor necrosis factor ( e.g. , remicade [ infliximab ] Medication know affect metabolism bone ( Principal Investigator discus PMO patient exclude enrollment ) . E. Miscellaneous Concurrent Medications · Methotrexate , interfere DNA synthesis , repair cellular replication . · Immunomodulatory agent antiproliferative activity . · Intraarticular injection Patients may receive maximum 1 intraarticular injection ( ONE JOINT ONLY ) every 6 month participate study . The dose corticosteroid inject exceed antiinflammatory equivalent dose Prednisone 40mg suspension . The dose volume adjust downward appropriate size joint . F. Laboratory Values Physical Examination Findings : For laboratory value , level show upper limit exclusion base specific test result . For weight , limit low limit . · Serum calcium &gt; 10.7 mg/dL ( &gt; 2.67 mmol/L ) · Serum creatinine &gt; 1.5 mg/dL ( 132.6 µmol/L ) · Urinary calcium creatinine ratio &gt; =1.0 ( mmol/mmol ) Total serum alkaline phosphatase &gt; 130 U/L ( Serum total alkaline phosphatase value give U.S. ; &gt; 311 U/L ( Argentina ) , &gt; 159 U/L ( Mexico ) . Body weight &lt; 40 kg G. Substance Abuse : · Subjects exclude history alcohol and/or drug abuse determine investigator H. Compliance : Subjects exclude exhibit suspect confirm poor compliance complete clinical study evaluation and/or clinical study require questionnaire .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Post-menopausal</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Parathyroid Hormone</keyword>
	<keyword>PTH</keyword>
	<keyword>ALX1-11</keyword>
</DOC>